TrialThe Journal of dermatology2021

Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma.

Hisashi Uhara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.